Viloxazine
Qelbree (viloxazine) is a small molecule pharmaceutical. Viloxazine was first approved as Qelbree on 2021-04-02. It is used to treat depression in the USA. Qelbree's patent is valid until 2033-02-07 (FDA).
| Trade Name | Qelbree |
|---|---|
| Common Name | Viloxazine |
| Indication | depression |
| Drug Class | Antidepressant; Norepinephrine reuptake inhibitor |
